Hepatic Disease in Patients With HIV

  • Author: Mark S. Sulkowski, MD (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 11/13/21 (What's New)


  • In randomized, controlled trials, the proportion of patients receiving combination ART who have grades 3 or 4 elevations in serum ALT or AST levels range from approximately 2% to 18%[Nuñez 2006]
  • Ritonavir-boosted PIs have not been associated with higher rates of hepatotoxicity
  • Liver enzyme elevations in large registration studies were infrequently symptomatic or dose limiting, and permanent liver injury was a distinctly rare event

Action required